Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Eli Lilly"


25 mentions found


Green day : A lot was working in the stock market on Friday. But it was hard to see through an ugly rotation out of this year's Big Tech winners in favor of more interest rate-sensitive stocks. Many of our hot tech stocks took a breather this week. It's more evidence of why Jim Cramer calls these two names "own, don't trade" stocks. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
Persons: Jim Cramer, Dow, Russell, Eli Lilly, Lilly, Wells Fargo, NII, toolmaker Stanley Black, Decker, Morgan Stanley, That's, Jim Cramer's, Jim Organizations: CNBC, Big Tech, Federal, Nasdaq, PPI, Fed, Meta, Nvidia, Apple, Ford, Abbott Laboratories, Jim Cramer's Charitable, Financial, Nurphoto, Getty Locations: Morphic, Wells, New York City, Mairo
Here are Thursday's biggest calls on Wall Street: Morgan Stanley reiterates Eli Lilly as overweight Morgan Stanley raised its price target on the stock to $1,083 per share from $1,023. "We are initiating RBBN with a Buy rating and $5 price target because the investment thesis has significantly improved." Rosenblatt reiterates Broadcom as buy Rosenblatt raised its price target on the stock to a Street high $2,400. Morgan Stanley downgrades Microchip to equal weight from overweight Morgan Stanley said the semis company has a "lofty" valuation. Morgan Stanley upgrades Telefonica Brasil to overweight from equal weight Morgan Stanley said it's bullish on shares of the LatAm telecom company.
Persons: Morgan Stanley, Eli Lilly, Rosenblatt, Goldman Sachs, Goldman, Mizuho, Truist, Wells, Guggenheim, it's, Jefferies downgrades Darden, Jefferies, Roblox, VIV, OW, Uber, McDonald's Organizations: Broadcom, AVGO, " Bank of America, Apple, Bank of America, JPMorgan, Nvidia, Digital Realty, Mizuho, Services, AMD, Silo AI, KBW, Guggenheim, Costco, Jefferies, Spotify, Telefonica Brasil, Energy, Uber, CART Locations: NYC, Europe, underperform, Olive, China
For passive investors, it's the best of times: They're seeing new highs on the two major cap-weighted indexes — S & P 500 and the Nasdaq Composite — with low volatility. One example is the Invesco S & P 500 Momentum ETF (SPMO) , which tracks the S & P 500 Momentum Index. That index follows the performance of stocks in the S & P 500 that have a high "momentum score." Momentum ETFs in 2024 S & P 500 up 18.1% Invesco S & P Momentum ETF (SPMO) up 39.9% iShares USA Momentum Factor (MTUM) up 28.5% Both ETFs also have concentrated bets. Why momentum is a risky strategy Let the buyer beware: Everyone looks like a genius holding on to winners in up markets.
Persons: Staples, Invesco, Eli Lilly, it's, It's, rebalanced, Rebalancing Organizations: Nasdaq, Tech, YTD Technology, Energy, Services, Momentum, Nvidia, Apple, Microsoft, Broadcom, Berkshire Hathaway, JPMorgan, Costco Locations: rebalancing
MicroStrategy is the latest company to announce a 10-for-1 stock split as its shares hit $1,340. AdvertisementIt's been a big year for stock splits. According to Bank of America, stock splits can be rocket fuel for prices. Shares of Chipotle have dropped 12% since its shares split 50-for-1 in late June. It represented one of the largest stock splits in the history of the New York Stock Exchange.
Persons: MicroStrategy, , It's, managements, Steve Sosnick, Eli Lilly, Sosnick Organizations: Service, Nvidia, Walmart, Broadcom, Chipotle, Sony, Lam Research, Texas Pacific, Interactive Brokers, Business, KLA Corp, Netflix, Intuit, Adobe, Bank of America, New York Stock Exchange Locations: Williams, Sonoma, Cintas
Pfizer on Thursday said it will move forward with a once-daily version of its weight loss pill, danuglipron, after it saw "encouraging" data in an ongoing early-stage trial. Pfizer is one of several drugmakers racing to win a slice of the market for a highly popular class of weight loss and diabetes drugs called GLP-1 agonists. At the time, the pharmaceutical giant said phase one trial data on the once-daily version would "inform a path forward." Pfizer's danuglipron is a GLP-1 that promotes weight loss in the same way as Novo Nordisk' s injection Wegovy and diabetes treatment Ozempic. But he said Pfizer was looking for potential licensing deals or earlier-stage weight loss drugs.
Persons: Albert Bourla, Pfizer's, Eli Lilly, Bourla, Mikael Dolsten, Dolsten Organizations: Pfizer, Novo Nordisk, U.S
Goldman Sachs raised its price target on Tesla, but it still sees a a decline for the electric vehicle maker. Analyst Chris Pierce upgraded his rating to buy from hold and assigned a $160 price target on Carvana, implying shares could jump 27.3%. His $77 price target on Walmart suggests the stock could jump nearly 10.2% over the next 12 months. Analyst Peter Keith assumed coverage of the retailer with a neutral rating and $156 price target, suggesting shares can add 5.7% over the next year. LLY YTD mountain LLY year to date — Pia Singh 5:51 a.m.: Goldman raises Tesla price target, but still sees stock slide Don't expect Tesla's recent momentum to last, according to Goldman Sachs The bank raised its price target on the electric vehicle maker to $248 from $175.
Persons: Tesla, Goldman Sachs, Eli Lilly, Needham, Chris Pierce, Pierce, — Pia Singh, Jefferies, Corey Tarlowe, Tarlowe, Piper Sandler, Peter Keith, Keith, Carter Gould, Gould, Goldman, Mark Delaney, Fred Imbert Organizations: CNBC, Barclays, Jefferies, Walmart, Fox Robotics, EV, Tesla Locations: Tuesday's
With the second half of the year underway, Oppenheimer is highlighting what it calls its top small- and midcap seasonal standout investment ideas. On the basis of price charts alone, Oppenheimer tapped midcap growth stocks as its top rotation idea from a technical perspective. Oppenheimer has a $20 price target on Zeta, implying 18% upside from Tuesday's close. In a note last month, RBC Capital Markets also rated Zeta outperform with a price target of $20. In this area, Oppenheimer likes Viking Therapeutics , reiterating the stock as one of its best ideas.
Persons: Oppenheimer, Russell, Brian Schwartz, Zeta, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, Jay Olson, Freshpet Organizations: Oppenheimer, Zeta Global Holdings, Zeta, RBC Capital Markets, Novo Nordisk's, Viking Therapeutics, Therapeutics Locations: Zeta, Novo
Joe Raedle | Getty ImagesAn Express Scripts spokesperson said "the prices of insulin and other medicines are set by their manufacturers, who have raised list prices repeatedly." The FTC's investigation into insulin prices also examines drugmakers, but it is unclear whether they will be named in the upcoming lawsuits, Politico reported, citing sources. Eli Lilly , French drugmaker Sanofi and Danish pharmaceutical company Novo Nordisk control roughly 90% of the U.S. insulin market. They also create lists of medications – or formularies – that are covered by insurance and reimburse pharmacies for prescriptions. Pharmacist Thomas Jensen looks over a prescription drug at the Rock Canyon Pharmacy in Provo, Utah, on May 9, 2019.
Persons: Lina Khan, Tom Williams, Joe Raedle, Eli Lilly, Sanofi, Thomas Jensen, George Frey Organizations: Trade, Financial Services, General Government, CQ, Inc, Getty, Federal Trade Commission, CNBC, UnitedHealth, CVS, Politico, Novo Nordisk, Pharmacy Locations: Miami , Florida, Danish, U.S, Provo , Utah
Joe Raedle | Getty ImagesAn Express Scripts spokesperson said the "prices of insulin and other medicines are set by their manufacturers, who have raised list prices repeatedly." They also create lists of medications — or formularies — that are covered by insurance and reimburse pharmacies for prescriptions. The investigation into insulin prices also examines drugmakers, but it is unclear whether they will be named in the upcoming lawsuits, Politico reported, citing people familiar with the matter. Eli Lilly , French drugmaker Sanofi and Danish pharmaceutical company Novo Nordisk control roughly 90% of the U.S. insulin market. Pharmacist Thomas Jensen looks over a prescription drug at the Rock Canyon Pharmacy in Provo, Utah, on May 9, 2019.
Persons: Lina Khan, Tom Williams, Joe Raedle, PBMs, Eli Lilly, Sanofi, Thomas Jensen, George Frey Organizations: Trade, Financial Services, General Government, CQ, Inc, Getty, Federal Trade Commission, CNBC, UnitedHealth, CVS, FTC, Politico, Novo Nordisk, Pharmacy Locations: Miami, U.S, Danish, Provo , Utah
TD Cowen reiterates Meta as buy TD Cowen raised its price target on Meta to $600 per share from $530. Bank of America downgrades Visa & Mastercard to neutral from buy Bank of America said it sees "limited upside" for the payment stocks. Bank of America downgrades WK Kellogg to underperform from neutral Bank of America said it sees weakening industry trends for WK Kellogg. "We're initiating coverage of Bausch + Lomb (BLCO) with an Outperform rating and $19 price target." Bank of America initiates Composecure as buy Bank of America said it's bullish on shares of the metal payment card manufacturer.
Persons: Bernstein, Iris, it's bullish, Argus, Teva, Piper Sandler downgrades, Piper, Jefferies, Redburn, Goldman Sachs, Tesla, Goldman, Eli Lilly, Morgan Stanley, Needham, BTIG, it's, TD Cowen, Meta, WK Kellogg, Cobra Kai, Truist, Nomura, Raymond James, Bausch Organizations: Iris Energy, Walmart, Fox Robotics, Spotify, Oracle, Barclays, Microsoft, Citi, Quest, Bank of America, MKS, Southwest Citi, Southwest Airlines, Amazon, YouTube, Meta, " Bank of America, Visa, Mastercard, of America, SNAP, Netflix, Apple, Nvidia Locations: Mounjaro, Alaska, Southwest, underperform
CNBC's Jim Cramer on Wednesday reviewed eight stocks that could join the coveted "trillion-dollar stock club," pinpointing pharmaceutical giant Eli Lilly and electric vehicle maker Tesla as top contenders. Currently, tech giants Apple , Microsoft , Nvidia , Alphabet , Amazon and Meta are the only companies on the market to surpass $1 trillion in market cap. "To me, it's going to be Lilly up next," Cramer said. "But the sheer popularity of Tesla might allow Musk to sneak back into the top rung, turning the Super Six back once again into the Magnificent Seven."
Persons: CNBC's Jim Cramer, Eli Lilly, Tesla, Lilly, Cramer, Musk Organizations: Apple, Microsoft, Nvidia
CNBC's Jim Cramer on Wednesday gave his take on Hims & Hers Health , a digital platform that offers telehealth services, particularly for sexual health, mental health, weight loss and skin care. Cramer suggested it might be worth starting a position in the stock now that it's pulled back some from recent highs. "While it makes sense that the stock roared on this compounded GLP-1 news, I don't love that it's now trading on what's essentially a temporary business," he said. Those great first quarter numbers didn't have any benefit from knock-off GLP-1s, and I bet the business stays strong." Hims & Hers Health did not respond immediately to request for comment.
Persons: CNBC's Jim Cramer, Cramer, it's, I'd, , Eli Lilly, dalliance Organizations: Wednesday, HIMS, Novo Nordisk
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly could be next to cross $1 trillion mark, says Jim Cramer'Mad Money' host Jim Cramer looks at what companies are in the running to join the elite $1 trillion club.
Persons: Eli Lilly, Jim Cramer
AMZN YTD mountain Amazon YTD We begin with Amazon 's move, which has been fueled by strength in its three core businesses. GOOGL YTD mountain Alphabet YTD Alphabet has been gaining steam in recent months on similar cloud tailwinds but also improving sentiment around its AI capabilities. META YTD mountain Meta Platforms YTD Meta Platforms ' stock has fully recovered all of its first-quarter earnings losses. LLY YTD mountain Eli Lilly YTD We are also increasing our Eli Lilly price target – taking it to $1,000 per share from $850. PANW YTD mountain Palo Alto Networks YTD One more stock we're raising our price target for is Palo Alto Networks .
Persons: Eli Lilly, Eli Lilly YTD, There's, donanemab, We're, Jim Cramer's, Jim Cramer, Jim, Beata Zawrzel Organizations: Palo Alto Networks, Amazon, Jefferies, Facebook, Alto Networks, CNBC, Google, Nurphoto, Getty Locations: CIOs, United States, Indiana, Palo
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. KeyBanc raised its price target on the Club chipmaker's stock to $180 per share from $130. New research indicated that tirzepatide, the active ingredient in Lilly's Mounjaro for diabetes and Zepbound for weight loss leads to more weight loss than Novo Nordisk's semaglutide. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Goldman Sachs, Piper Sandler, , KeyBanc, Eli Lilly, Lilly, Jim Cramer's, Jim Organizations: CNBC, Nasdaq, Apple, Big Tech, Nvidia, Club, Blackwell, Novo Nordisk's semaglutide
Helen of Troy — The housewares stock plummeted nearly 28%, hitting a new 52-week low during the session. The company posted an earnings miss for its first quarter of fiscal 2025 before the bell, earning 99 cents per share, excluding items. Lucid — The electric vehicle company's stock added nearly 1% after rallying about 8% in the previous session. Lucid jumped after the firm said it delivered 2,394 vehicles in the second quarter, marking a 70% year-over-year increase. Tesla — Shares of the electric vehicle company popped more than 4%.
Persons: Blackwell, Helen of Troy —, FactSet, UiPath, Lucid, Eli Lilly's Mounjaro, Eli Lilly, Morgan Stanley, Corning, Yun Li, Pia Singh, Sarah Min, Darla Mercado Organizations: Nvidia, UBS, BP — U.S, Novo Nordisk, Novo Nordisk's Ozempic, Sony, Paramount, National Amusements, Skydance Media, Apollo, CNBC Locations: Novo
Morphic Holding — Shares surged more than 75% on news that Eli Lilly will acquire the biopharma company in a $3.2 billion deal . The deal will give Eli Lilly access to Morphic's portfolio of treatments in development, such as those for ulcerative colitis and Crohn's disease. Eli Lilly shares inched up 0.2% on the news. SolarEdge — The energy company rose 5% after Bank of America upgraded shares to neutral from underperform, citing an attractive entry point for investors. Gilead — Shares of the biotech stock rose more than 2% after an upgrade to outperform from market perform at Raymond James.
Persons: Eli Lilly, SolarEdge, Guggenheim, ServiceNow, John DiFucci, Baird, Gilead —, Raymond James, Gilead, Sarah Min, Jesse Pound, Michelle Fox, Yun Li Organizations: Paramount, Skydance Media, Bank of America, PNC, UBS, KeyCorp, Columbia,
CNBC's Jim Cramer on Monday suggested that it is not just Big Tech that has the capacity to lead the market. Cramer highlighted Eli Lilly , a pharmaceutical giant whose stock hit a new high during Monday's session and is currently valued at about $870 billion. "These companies maintain their status through invention," Cramer said of huge names such as Amazon , Meta , Apple , Microsoft , Alphabet and Nvidia . The question is why other companies aren't doing the same things that Eli Lilly's doing to get in the winner's circle." Eli Lilly did not immediately respond to CNBC's request for comment.
Persons: CNBC's Jim Cramer, Cramer, Eli Lilly, Eli Lilly's, Eli Lilly's Alzheimer's, Organizations: Big Tech, U.S . Food, Drug Administration, Apple, Microsoft, Nvidia Locations: U.S
Skydance and its financial backers will invest more than $8 billion into Paramount and to acquire National Amusements, Paramount's controlling shareholder. Morphic Holding – Shares rallied 75% on news that Eli Lilly will acquire the biopharmaceutical company in a $3.2 billion deal . The deal will give Eli Lilly access to Morphic's portfolio of treatments in development, such as those for ulcerative colitis and Crohn's disease. Shares of Eli Lilly advanced 1.3% on the news. Boeing – Shares fell slightly after the airplane maker agreed to plead guilty to criminal fraud related to the fatal 737 Max crashes, sparing Boeing from a trial.
Persons: Eli Lilly, BofA, Corning, Guggenheim, Max, Grayson, Raymond James, Samantha Subin, Pia Singh, Hakyung Kim, Sarah Min, Michelle Fox Organizations: Paramount Global, Skydance Media, Skydance, Paramount, National, Morphic, Ideaya Biosciences, Bank of America, Boeing –, Boeing, ., CNBC, Devon Energy, Gilead Sciences Locations: Columbia, Stifel, Williston, Gilead
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Shares of the iPhone maker hit a new high after the opening. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Jim, Morgan Stanley, Wells, Eli Lilly, Joe Biden, Lilly's donanemab, Jim Cramer's Organizations: CNBC, Microsoft, Apple, Palo Alto Networks, Facebook, Palo, Bulls, Bears Locations: Palo, Palo Alto
CNN —People taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study. But 82% of people taking tirzepatide reached this important clinical benchmark, compared with about 67% of those taking semaglutide. Average weight loss was also consistently higher among those taking tirzepatide over time. And by one year, average weight loss was nearly double for those taking tirzepatide — more than 11%, compared with about 6% for those taking semaglutide. According to the new study, individuals with type 2 diabetes had less significant weight loss than those without a diagnosis — but average weight loss was still greater among those taking tirzepatide.
Persons: tirzepatide, Eli Lilly, , Dr, Sanjay Gupta, CNN’s Brenda Goodman Organizations: CNN, US Food and Drug Administration, Novo Nordisk, semaglutide, FDA, CNN Health Locations: Truveta
We don't say they have a secular wind at their backs. We don't say: Apple's business is much better than we thought. They keep coming back to one main point: You can't have these companies dominate without something bad happening to the stock market. Let me present a different, factual manifesto: The companies with these amazing gains are companies that just don't stop inventing. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
Persons: Eli Lilly, Joe Biden, Biden, Lilly, , Tesla, Elon Musk, Jim Cramer's, Jim Cramer, Jim Organizations: Amazon, Microsoft, Apple, Nvidia, Nasdaq, pharma, Novo Nordisk, National Football League, YouTube, Web Services, Costco, Walmart, Jim Cramer's Charitable, CNBC, Facebook, Google Locations: Lilly
Tema ETFs has been capitalizing on the risk appetite for weight loss stocks. The firm's founder and CEO Maurits Pot thinks the winning weight loss trade isn't based on just hype. "We could see a world where the majority of the world's population takes a GLP-1, not just for weight loss, but for other diseases." His top holdings include Mounjaro manufacturer Eli Lilly and Ozempic and Wegovy maker Novo Nordisk. Eli Lilly is up 57% so far this year, while Novo Nordisk is up 38%.
Persons: Maurits Pot, Pot, Eli Lilly, Ozempic Organizations: Cardiometabolic, Novo Nordisk Locations: Tema, Novo
Analysts who have been following companies on the cutting edge of using generative AI for drug discovery say it is still very early days. But these endorsements haven't lifted Recursion shares out of a slump. RXRX 1Y mountain Recursion shares over the past year. The drug company will be a beta user of Recursion's LOWE (Large Language Model-Orchestrated Workflow Engine) and the pair are also partnering on oncology research. SDGR 1Y mountain Schrodinger shares over the past year.
Persons: Scott Schoenhaus, Chris Gibson, Jensen Huang, Leerink, Mani Foroohar, Foroohar, Recursion's, KeyBanc's Schoenhaus, Needham, Gil Blum, it's, Recursion's LOWE, Blum, Eli Lilly, AbCellera, KeyBanc's, Schoenhaus, FactSet, Allison Bratzel, Piper Sandler, Goldman Sachs, Salveen Richter, Peter Lawson, Lawson, Japan's Takeda, Schrodinger, Leerink's Foroohar Organizations: Analysts, Capital, Nvidia, ARK Investment Management, REC, CCM, Union, Bayer, Therapeutics, Dynamo, RLY, Barclays, Japan's Locations: U.S, biopharma, Biohive
The June employment report on Friday morning came in slightly better than expected with the economy adding 206,000 nonfarm jobs versus 200,000 expected. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. Top things to watch Friday, July 5Stocks were mixed slightly Friday following another record S&P 500 th holiday. The June employment report on Friday morning came in slightly better than expected with the economy adding 206,000 nonfarm jobs versus 200,000 expected.
Persons: Eli Lilly, Jefferies, Jim Cramer's, Jim Cramer, Jim, Constellation Brands Novo Nordisk Eli Lilly Samsung Organizations: Treasury, Constellation Brands, JPMorgan, Novo Nordisk, Samsung Electronics, Jim Cramer's Charitable, CNBC, Constellation Brands Novo Nordisk, Constellation Brands Novo Nordisk Eli Lilly Samsung Electronics
Total: 25